<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815100</url>
  </required_header>
  <id_info>
    <org_study_id>Riviera/09</org_study_id>
    <nct_id>NCT00815100</nct_id>
  </id_info>
  <brief_title>Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Canarias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario de Canarias</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether a pure heart rate-lowering agent&#xD;
      (Ivabradine) reduces vascular inflammatory stress in patients with acute coronary syndromes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The activation of inflammatory pathways plays an important contributory role in coronary&#xD;
      plaque instability and subsequent rupture, which can lead to the development of acute&#xD;
      coronary syndromes. Elevated levels of serum inflammatory markers such as high-sensitivity&#xD;
      C-reactive protein (hs-CRP) represent independent risk factors for further cardiovascular&#xD;
      events. Raised resting heart rate (HR) has been shown to be associated with cardiovascular&#xD;
      events. Ivabradine is a new HR-reducing agent, which has demonstrated antianginal and&#xD;
      anti-ischemic properties in patients with stable angina. In an atherosclerosis model,&#xD;
      selective HR reduction with ivabradine has been shown to decrease markers of vascular&#xD;
      oxidative stress, to improve endothelial function, and to reduce atherosclerotic plaque&#xD;
      formation. We hypothesized that the addition of ivabradine to standard medical therapy has a&#xD;
      beneficial effect on markers of inflammatory stress in acute coronary syndrome patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2009</start_date>
  <completion_date type="Actual">September 7, 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whether initiation of ivabradine therapy in patients with acute coronary syndromes immediately after hospital admission decreases high-sensitivity C-reactive protein.</measure>
    <time_frame>day 4 and day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whether initiation of ivabradine therapy decreases the occurrence of ischemic events (death, nonfatal myocardial infarction, unstable angina, urgent revascularization, cardiac arrest) in patients with acute coronary syndromes.</measure>
    <time_frame>day 30, 90, 180 and 360</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).</description>
    <arm_group_label>Ivabradine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female.&#xD;
&#xD;
          2. Age &gt; 18 years.&#xD;
&#xD;
          3. Ischemic symptoms suspected to represent a non-ST segment elevation acute coronary&#xD;
             syndrome defined as:&#xD;
&#xD;
             Clinical history consistent with new onset, or a worsening pattern, of characteristic&#xD;
             ischemic chest pain occuring at rest or with minimal exertion (lasting longer than 10&#xD;
             min) and planned to be managed with an early invasive strategy with intention to&#xD;
             perform a percutaneous coronary intervention as early as possible and not later than&#xD;
             72 hours of randomization, and at least one of the following:&#xD;
&#xD;
               1. ECG changes compatible with new ischemia (ST depression of at least 1 mm or&#xD;
                  transient ST elevation or ST elevation of &lt;1 mm or T wave inversion &gt;3 mm in at&#xD;
                  least 2 contiguous leads; or&#xD;
&#xD;
               2. Already elevated cardiac enzymes (eg, CK-MB) or biomarkers (troponin I or T)&#xD;
                  above the upper limit of normal.&#xD;
&#xD;
          4. Patients should be in sinus rhythm with a resting HR of &gt; 60 beats per minute on a&#xD;
             resting standard 12-lead ECG.&#xD;
&#xD;
          5. Written informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients unlikely to cooperate in the study or with inability or unwillingness to give&#xD;
             informed consent.&#xD;
&#xD;
          2. Pregnant or breast-feeding women or women of childbearing potential.&#xD;
&#xD;
          3. Patients with recent (&lt; 6 months) myocardial infarction or coronary revascularization&#xD;
             or with a history of stroke or cerebral transient ischemic attack within the preceding&#xD;
             3 months or scheduled for revascularization (percutaneous coronary intervention and&#xD;
             coronary artery bypass graft).&#xD;
&#xD;
          4. Patients with at least 1 of the following criteria:&#xD;
&#xD;
               -  Implanted pacemaker or implantable cardioverter defibrillator.&#xD;
&#xD;
               -  Valvular disease likely to require surgery within the next 2 years.&#xD;
&#xD;
               -  Sick sinus syndrome, sinoatrial block, congenital long QT syndrome, complete&#xD;
                  atrioventricular block.&#xD;
&#xD;
               -  Expectation of death from other illness during the course of the trial.&#xD;
&#xD;
               -  Known severe liver or renal disease.&#xD;
&#xD;
               -  Requiring or likely to require the following medications: macrolide antibiotics,&#xD;
                  cyclosporin, gestodene, antiretroviral drugs or azole antifungals such as&#xD;
                  ketoconazole or with known hereditary problems of galactose intolerance, Lapp&#xD;
                  lactase deficiency, or glucose-galactose malabsorption.&#xD;
&#xD;
          5. Patients with systemic or cardiac inflammatory processes with the exception of&#xD;
             atherosclerosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 25, 2008</study_first_submitted>
  <study_first_submitted_qc>December 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2008</study_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ivabradine</keyword>
  <keyword>Acute coronary syndrome.</keyword>
  <keyword>Inflammation</keyword>
  <keyword>C-reactive protein</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

